The arrow of the times: the Chinese power behind the mRNA vaccine

In the context of the global new crown pandemic, many countries have invested a lot of manpower and material resources in the research and development of the new crown vaccine; it is no exaggeration to say that the research and development of the new crown vaccine has become an arena for scientific and technological strength and even national strength among major countries
.

Up to now, dozens of new crown vaccine candidates have entered the clinical trial stage, and at least no less than 100 are undergoing pre-clinical animal experiments
.

According to the technical route, the new crown vaccines currently under research and on the market around the world are mainly divided into four types: inactivated vaccines, recombinant protein vaccines, adenovirus vector vaccines, and mRNA vaccines
.

Judging from the data published so far, there is no doubt that mRNA vaccines are the focus of competition, and they are also the main inoculation varieties with a high probability of new crown vaccines in the future
.

Up to now, the two mRNA vaccines on the global market are in the United States and Europe, and China has also shown ambitious research and development plans in this direction.
According to public information, many Chinese companies have already developed mRNA COVID-19 vaccine research projects
.

1.
Aibo Biological

Founded in Suzhou Industrial Park at the beginning of 2019, Aibo Biology is one of the earliest companies engaged in mRNA drug research and development in China.
In 2020, the Joint Institute of Military Medicine of the Academy of Military Sciences and Yunnan Watson Biology successfully developed the first Chinese new crown ARCoV vaccine to enter the clinic
.

InBev, founder of Aibo Bio, graduated from Fudan University with a bachelor's degree in biology, and a doctorate in pharmacy from Northeastern University in Boston, USA.
He has worked in Moderna, Trucode Gene Repair and other companies in the United States, and returned to China in 2019 to start a business
.

A big advantage of Abbio's mRNA vaccine is that it can be stored at 2-8 degrees Celsius
.

Aibo Biological and Watson Biological, a listed company in A shares, jointly promote the clinical and commercialization of mRNA vaccines.
It has completed phase II clinical trials and is the most advanced one among domestic mRNA vaccines
.

According to data from the online database ClinicalTrials.
gov, in the phase III clinical trial, Watson Bioplans to recruit about 28,000 volunteers over 18 years old worldwide, of which at least 25% of the volunteers are over 60 years old
.

Abbio has completed several rounds of financing in the primary market.
The most recent financing was 600 million yuan.
Rumor has it that the valuation is already at the tens of billions level
.

2.
Si Microbiology

Smicrobiology was founded in 2016 in Shanghai Zhangjiang Medicine Valley.
The company's core competitiveness lies in its mRNA synthesis platform and LPP nano-delivery platform
.

The founder and CEO of Si Microbiology, Dr.
Hangwen Li, received his Ph.
D.
from the University of Texas Anderson Cancer Center
.

In response to the new crown pneumonia epidemic, in January 2020, Sri Microbiology cooperated with the Chinese Center for Disease Control and Prevention and Dongfang Hospital affiliated to Tongji University to urgently launch the mRNA new crown vaccine research and development project
.

On January 4, 2021, the first phase of the mRNA new crown vaccine of Sri Lanka Microbiology was approved.
It is the second domestic mRNA new crown vaccine product to obtain clinical approval
.

According to public information, S.
Microbe stated that its new-generation COVID-19 vaccine can effectively prevent a variety of mutant strains including South African strains, Brazilian strains and Indian strains
.

Microbiology just completed a RMB 1.
2 billion financing this month for the advancement of clinical trials and the expansion of production capacity
.

3.
Livanda

Livanda was registered and established in Hengqin, Zhuhai in June 2019, and has an independent mRNA R&D and production technology platform
.

Livanda founder Dr.
Peng Yucai, biopharmaceutical scientist, PhD from McGill University in Canada, worked as a senior scientist at Biogen in the United States, returned to China in 2010 to establish the Livzon Group monoclonal antibody drug development platform
.

On March 16, 2021, the novel coronavirus mRNA vaccine developed by Livanda was approved and issued by the National Medical Products Administration in the "Drug Clinical Trial Approval Document".
It is the third domestic mRNA vaccine to obtain clinical approval
.

On June 1, Amy Vaccine announced that it had completed the acquisition of Zhuhai Livanda Biotechnology Co.
, Ltd.
on May 31, holding 50.
1546% of its shareholding
.

4.
Believe in biology

Convinced Bio was established in November 2019
.

Dr.

Compared with the in-depth cooperation between Aibo Biological and Watson Biological, in December 2020, Zhifei Biological subscribed for a 10.

5.

Blue Magpie Bio was established in Shanghai in April 2019, focusing on the research and development of mRNA vaccines and treatment methods based on mRNA drugs

Yu Hang, the founder of Lanque Biology, graduated from Zhu Kezhen College of Zhejiang University with a bachelor's degree; in 2008, he obtained a master's degree in artificial intelligence from the University of Florida

Relying on the blessings of the Fudan University and Jiaotong University teams, Lan Que has a very solid academic backing.

end

In addition to the five companies listed above, domestic companies involved in the research and development of mRNA vaccines include Regis Bio, Hocun Nano, and Minuo Hengkang

This vigorous mRNA vaccine research and development competition is neither the official agency as the protagonist nor the leadership of much administrative will behind it.

Thanks to the pharmaceutical policy reform in 2015, the decadent rentiers have been gradually wiped out of the industry's stage.

Perhaps there has been a partial bubble in this industry, but the bubble is not necessarily a bad thing.
Just like the crazy tulip bubble that year, the cultivation of tulips is still one of the dominant industries in the Netherlands
.

Under the nourishment and baptism of the bubble, the innovators who truly master the core technology are leading the entire industry to a higher level with an irreversible development attitude, and even in line with the international trend
.